Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone + Anlotinib in Advanced Esophageal Cancer
NCT05866510Phase 2Unknown
- Sponsor
- Peking University
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and anlotinib in esophageal carcinoma, sponsored by Peking University. Primary endpoint: Objective Response Rate up to 1 year. Status: unknown.
02
Drugs
utideloneanlotinib
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT05866510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866510.